BASIL-2 Results paper: Andrew W Bradbury, Catherine A Moakes, Matthew Popplewell, Lewis Meecham, Gareth R Bate, Lisa Kelly, Ian Chetter, Athanasios Diamantopoulos, Arul Ganeshan, Jack Hall, Simon Hobbs, Kim Houlind, Hugh Jarrett, Suzanne Lockyer, Jonas Malmstedt, Jai V Patel, Smitaa Patel, S Tawqueer Rashid, Athanasios Saratzis, Gemma Slinn, D Julian A Scott, Hany Zayed, Jonathan J Deeks, on behalf of the BASIL-2 Investigators (2023), A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial in The Lancet, Published online 25 April 2023. DOI: https://doi.org/10.1016/ S0140-6736(23)00462-2
Publication by Andrew Bradbury (BASIL-2 CI) & Gareth Bate (BASIL-2 Lead Research Nurse) Editor's Choice – A Comparison of Clinical Outcomes Between Primary Bypass and Secondary Bypass After Failed Plain Balloon Angioplasty in the Bypass versus Angioplasty for Severe Ischaemia of the Limb (BASIL) Trial
Publication by Kevin Barraclough and Professor Andrew Bradbury (BASIL-2 CI) Chronic limb threatening ischaemia .
Subgroup analysis by Popplewell et al. 2017 of patients randomised into the original BASIL trial with infrapopliteal disease reaffirming the need for RCTs such as BASIL-2 and BEST-CLI.
Article by Barry Katzen Endovascular therapy for critical limb ischaemia: When is enough, enough?
BASIL-2 Trial Protocol (Popplewell et al 2014, Bypass vesus angioplasty in severe ischaemia of the leg -2 (BASIL-2): study protocol for a randomised controlled trial), Trials 2016 17:11